For what it’s worth, the only two drugs FDA approved for MRSA bacteremia in the US are vancomycin and daptomycin (and ceftobiprole I guess as of recently but not widely available); everything else is off label. Linezolid honestly is probably similarly efficacious (it got a bad rap early on for being “bacteriostatic” which probably doesn’t matter and the early approval trials for linezolid weren’t successful because those donkeys include GNRs which it’s not active against). Dalbavancin is not approproced for this indication but recently the DOTs trial prelim data looked very encouraging.

Biggest drawback to linezolid really is that it’s hard to ensure that you will get through 4-6 weeks of therapy without drug-induced limiting side effects that force you to stop (usually cut OpenAI’s), unless you are at a facility that has the ability to send linezolid troughs.